Breast-Cancer-Portal

As the challenges of Individualized Medicine with regard to precision guided therapy continue to increase, information about the use of relevant biomarkers becomes increasingly important. Similarly, collaboration among pathologists, oncologists, molecular biologists, and human geneticists becomes increasingly crucial for planning therapy as precisely as possible.  

QuIP has set itself the task of accompanying pathologists in Germany and Europe in optimizing their examination results and supporting them in all relevant professional and organizational quality assurance activities. The Breast-Cancer-Portal is intended to serve pathologists as well as specialists in other disciplines and oncologists, for orientation at the interface between biomarker testing and therapy.

Two biomarker based treatment algorithms for early breast cancer and advanced/metastatic breast cancer are provided on the Breast-Cancer-Portal, based on both current medical guideline recommendations and new scientific evidence, with detailed explanations of the underlying tests. Information on biomarkers, tests, analyses, and treatment options is shown so that pathologists and oncology physicians can obtain concise information on this topic and the therapeutic implications.

Additional information in German can be found at the German Arbeitsgemeinschaft Gynäkologische Onkologie (AGO Recommendations). The German S3 guideline Breast Cancer can be found on the website of the German Association of the Scientific Medical Societies (AWMF).

References on the Portal

The underlying and utilized scientific literature for the portal content is cited in a dedicated "References" section for each respective algorithm passage and is also referenced and identified throughout the texts. The research literature listed reflects the current editorial processing status and is updated or supplemented as necessary.

Disclaimer

Please note: We provide the information on our Breast-Cancer-Portal to the best of our knowledge. However, please note that we cannot guarantee the completeness, accuracy and/or timeliness of the information. This is especially true for content on our website that originates from third parties and is merely linked by us. For current and also further information on the medications, the respective technical information should be consulted.

Furthermore, the subject matter is generally characterized by the fact that different pathologists can arrive at different conclusions when interpreting images. Therefore, we specify the exact data basis on which the evaluation of each reference slide is based. The evaluation of your own slides is solely your responsibility. Please feel free to contact us with any questions. 

Qualitätssicherungs-Initiative Pathologie GmbH

QuIP is supported by AstraZeneca, Lilly, Menarini Stemline, MSD Sharp & Dohme, Pierre Fabre and Sanofi.